A Message From Chaikin Analytics

Dear Reader,

Marc Chaikin just issued a shocking new prediction about AI.

And we encourage anyone with money in the markets to pay very close attention.

Why? Chaikin is one of Wall Street's most respected investment minds.

His former clients have included billionaires like Steve Cohen, owner of the New York Mets...

D.E. Shaw, founder of one of the world's leading money-management firms...

And George Soros, founder of the Quantum Fund with Jim Rogers...

He pioneered computerized trading on Wall Street.

His Chaikin Money Flow indicator is built into every Bloomberg trading terminal on Earth.

He used his 20-factor Power Gauge system to predict:

• The Covid Crash of 2020
• The Stealth Bear of 2022
• The "Liberation Day" Plunge of 2025
• And countless other events going back 50-plus years

His system flashed bullish on Micron before it soared 970% in one year...

Celestica before it soared 6,600%...

And Nvidia before it skyrocketed more than 50,000%...

But he's calling his new prediction the biggest and most important of his career.

According to Chaikin, a $248 trillion "White Swan" event is about to disrupt AI.

It involves a radical new breakthrough in AI data centers.

This new technology uses 99% less electricity.

It uses 99% less water.

It uses 99% less space than current data centers.

Yet it's more than 1 trillion times more powerful when it comes to generating major scientific breakthroughs.

"If our research is correct, This will shorten discovery timelines from years to days or even hours," says the veteran analyst.

That means breakthroughs that would take 5 years with current AI tech will come in just 5 days – accelerating timelines by 360-fold.

One former IBM executive calls this new tech: "A scientific instrument for the ages.

And it could secure America's AI dominance over China for generations.

Which is why the White House is spending billions to expedite the launch right now.

Even better?

The company behind this breakthrough recently flashed "bullish" in Chaikin's system.

Now he says it could be the best AI investment for at least the next 5 years.

Chaikin reveals all the details for free here, in his brand-new presentation.

He even reveals the name and ticker of the company behind the coming breakthrough about halfway through the video.

But fair warning: This is very timely information.

Chaikin says he reserves the right to take it offline at any moment.

So don't wait. Click the link above to check it out while you still can.

Sincerely,

Vic Lederman
Publisher, Chaikin Analytics

P.S. We recommend checking out Marc's presentation right now. Drop whatever you're doing. When this company's new AI tech launches, his research shows it'll render all current AI tech virtually obsolete – instantly. How? By accelerating AI breakthrough times 360X. (Breakthroughs that were supposed to come in 5 years could come in 5 days.) The time to invest is now, he says. And he reveals the full story – and stock ticker – here, for free. Don't delay. This launch will happen before the end of this year.

Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions

Submitted by Sam Quirke. First Published: 10/27/2026.

Apple Inc. (NASDAQ: AAPL) shares hit an all-time high on Oct. 23 and are currently trading just below it, around $345, up nearly 30% over the past year. Driving the latest leg of the rally is the iPhone Duo, Apple’s first foldable, which sold out within minutes of its recent launch despite its $1,999 price tag. Delivery estimates now stretch into late January, and Apple has been scrambling to increase production.

For a company long dismissed as overly dependent on incremental upgrades, demand like this marks a real change of pace. Yet not everyone is convinced: Apple has just received a rare downgrade, and mounting concerns suggest its record valuation leaves little room for error.

With earnings due on Nov. 2, the question is whether the foldable frenzy marks the start of something lasting—or whether Apple’s shares might have run too far, too fast.

iPhone Duo Demand Is Outpacing Supply

While there were doubts about how hungry consumers would be for the Duo, the latest demand signals are hard to dispute. The foldable sold out almost immediately, and Apple’s website now quotes delivery dates in late January, implying waits of around three months for a phone that costs nearly $2,000. Behind the scenes, Apple has reportedly scrambled to boost output, with some reports pointing to an increase of as much as 30% in planned production. The launch hasn’t been entirely smooth, however. On Oct. 26, Apple acknowledged that a small number of Duo units had experienced inner-display problems.

It isn’t just the foldable model doing well. Apple’s new iPhone 18 Pro has also been selling well, reportedly capturing about a third of China’s smartphone market in its opening week. That’s a reminder that Apple’s premium appeal remains strong in a market where it has often struggled. Taken together, the results show this is still a company whose products people will queue around the block for.

For the bulls, that matters well beyond new hardware. A richer lineup lifts average selling prices, draws more users deeper into Apple’s lucrative services ecosystem and hints that the foldable could open an entirely new product category. After years of being written off as a slow grower, Apple’s iPhone unit sales suddenly look like a growth story again.

Apple's Valuation Gives Wall Street Reason to Pause

Not everyone is buying it, though. On Oct. 20, Loop Capital cut its rating on Apple to Hold, arguing that iPhone shipments trimmed earlier in the year may not be recovered after all and flagging the risk that rising memory costs could eat into margins. The firm still likes Apple’s long-term services story but reckons the stock needs a “fundamental catalyst reset” after its run to five-year valuation highs.

The downgrade also follows reports that Apple reduced iPhone 18 Pro component orders, raising further questions about demand. For now, however, that view remains in the minority, with the consensus rating still a Moderate Buy.

That valuation is the crux of the bear case. Apple trades at nearly 40 times earnings, a rich multiple for a business whose growth, while healthy, is hardly explosive. At that price, strong demand alone may not be enough: if memory costs squeeze margins or high prices crimp sales of standard iPhone models, the shares have plenty of room to fall. In other words, the real question isn’t whether the Duo will be a hit. It’s whether it will be a big enough hit to justify what investors are being asked to pay.

Apple's Nov. 2 Earnings Put Guidance in Focus

One wrinkle for anyone hoping the Nov. 2 earnings report will settle the argument: it probably won’t, at least not directly. Apple’s fiscal fourth quarter ended in September, before the Duo went on sale, so the headline numbers will say little about how the foldable is actually selling.

The real tell will be the guidance. Investors will be looking for a December-quarter revenue outlook that comfortably clears Wall Street’s bar, along with reassurance that rising memory costs aren’t eating into margins.

Can Apple's Earnings Justify Its Record Valuation?

Ahead of the Nov. 2 report, investors are right to ask whether red-hot Duo demand can not only justify Apple’s record run but also send the stock to fresh highs. The bulls’ argument on the product itself is convincing: the foldable is a clear hit, the China numbers are encouraging, and Apple finally has a story to tell beyond another round of iPhone refreshes.

The stock, though, is a different question. At near-record levels and nearly 40 times earnings, Apple needs more than sold-out queues; it needs a December outlook strong enough to prove the frenzy will translate into profit. A sold-out foldable might be reason enough to admire Apple again, but it will take a convincing report and outlook to justify paying up for the stock.

A Message From Brownstone Research

Jeff Brown is the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years in advance. He's now predicting Elon Musk is about to open a new wealth window. Click here to see the details or read more below because the last three times this window opened, those who acted had a chance to walk away with generational wealth.

Dear Reader,

Have you seen this Elon Musk new project?

He called it "the most epic AI project in history…"

Because it could help him secure 50 times MORE computing power than the entire rest of the world.

This is all part of Elon Musk's $320 trillion masterplan…

A blueprint to completely dominate the entire AI industry.

And I'm pretty sure this is keeping executives at Amazon, Microsoft, and Google up at night.

But what does this mean for you?

Well, Elon is predicting this could be 180 times bigger than the SpaceX IPO.

That IPO minted 4,400 millionaires overnight.

If this is 180 times bigger…

Just imagine how many more Americans will become millionaires.

Will you be one of them?

Or will you just watch others get rich from the sidelines?

Click here to see the details and decide for yourself.

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

By Bridget Bennett. Originally Published: 10/19/2026.

Rate and energy headlines have kept the broad market jumpy, yet one sector continues to find buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

The money isn’t chasing a single drug. It’s following a shift in where artificial intelligence (AI) is being applied. Chips, code and business data defined the first waves of the AI trade. The next target is the human body—a data set with 8 billion members.

That shift puts some of medicine’s biggest challenges—cancer, heart disease, dementia and aging—squarely in focus. These conditions affect billions of lives, and AI is giving researchers new ways to understand their underlying biology. Once-daunting medical mysteries are becoming problems that can increasingly be modeled, tested and addressed with greater precision.

AI Is Turning the Medical Race Into an Engineering Race

The framework comes from Keith Kaplan, CEO of TradeSmith, who calls this wave biointelligence. Earlier AI waves read chips, code and business data. This one reads people—a market that never runs out of customers.

Wall Street has started pricing that in. Eli Lilly and Company (NYSE: LLY) briefly touched a $1 trillion valuation last November, a first for a healthcare company. In August, Moderna (NASDAQ: MRNA) and partner Merck & Co. (NYSE: MRK) reported that their personalized cancer vaccine met its primary and key secondary endpoints in a Phase 3 melanoma trial—the first late-stage win for an mRNA cancer therapy.

Two trends collided to make that possible. The cost of sequencing a human genome fell from about $100 million in 2001 to a few hundred dollars, while AI became exceptionally good at finding patterns in oceans of data. Kaplan splits the opportunity into three moves: read the body, rewrite it and replace what can’t be saved.

Reading, Rewriting and Replacing the Body Have Reached the Clinic

Reading already has a face. Ann Johnson lost her speech to a brainstem stroke at 30. Eighteen years later, a University of California, San Francisco, team used AI to decode her brain signals into speech, placing 253 electrodes on the surface of her brain and translating her attempts to speak into words at about 80 per minute, compared with 14 per minute on her previous device. The electrodes weren’t new—the AI that could interpret them was.

Rewriting looks like Moderna’s personalized cancer vaccine, which uses AI to analyze mutations in a melanoma patient’s tumor and identify up to 34 targets for the patient’s immune system to attack. Replacing is further out, with gene-edited pig organs aimed at a transplant list of roughly 100,000 Americans.

Platforms That Compound Beat Biotech Lottery Tickets

Here’s where it gets frustrating for investors. The purest brain-interface plays, including Neuralink, Synchron and Paradromics, are private, and the closest public door is Medtronic (NYSE: MDT).

That pushes the public trade toward data, platforms and distribution. The old biotech model was to pick the right molecule or risk losing everything. Now, every test Guardant Health (NASDAQ: GH) runs sharpens the next one, and every patient in the Tempus AI (NASDAQ: TEM) library improves the next answer. These businesses compound.

In Kaplan’s framing, the group is a decade-long menu, not a checklist. Start with profitable large caps and toll-booth names, size speculative positions small and expect biotech-style swings. He sorts 12 biointelligence stocks into four risk groups in a free report, which is where the four names below come from.

Blood Tests and Sequencers Get Paid on Every Breakthrough

Guardant Health’s Shield test screens for colorectal cancer, the second-deadliest cancer in the United States, from an ordinary blood draw. About a third of eligible adults skip screening rather than undergo a colonoscopy, and a blood test changes that equation.

Adoption is moving fast. Second-quarter screening revenue reached $52.9 million, up from $14.8 million a year earlier, on roughly 66,000 Shield tests versus 16,000. The test has entered American Cancer Society guidelines, UnitedHealth Group (NYSE: UNH) now covers it, and about 70 million people have access to it.

Kaplan expects a strong report in late October, since early detection costs insurers far less than late-stage treatment.

Illumina (NASDAQ: ILMN) sells the shovels in this gold rush. It builds the sequencers behind falling genome costs, then sells the reagent kits those machines consume for years.

Three lost years tied to a botched acquisition are behind it. Guidance moved up to a range of $4.60 billion to $4.64 billion, and the stock rejoined the S&P 500 in September. Kaplan’s view is that Illumina benefits from every trial that starts with sequencing, which makes sequencing volume the number to watch.

Pharma Scale and a Cash-Burning Cancer Bet Set the Risk Range

Eli Lilly anchors the steadier end. Revenue hit $65 billion last year, up 45%, and guidance calls for $85 billion to $87 billion this year. Beyond Mounjaro, an oral GLP-1 pill won approval in April, and retatrutide, an experimental triple agonist, delivered average weight loss of 71 pounds in Phase 3, with a filing targeted for early 2027.

The bigger story may sit outside weight loss. Lilly runs 42 Phase 3 programs, with about three-quarters of its new medicines outside GLP-1s, and committed up to $2.75 billion in March for exclusive rights to an AI drug discovery platform.

Moderna sits at the other extreme. Nine trials with Merck span melanoma, lung, bladder and kidney cancer, and the AI that picks targets for each patient is the product. The catch is a quarterly loss of roughly $800 million.

Nasdaq-100 inclusion took effect in October, forcing index-tracking funds to buy, and full Phase 3 data is expected later this month, with earnings right behind it.

Waiting until after earnings may be sensible, according to Kaplan, who considers the stock speculative.

Data Engines, Not Single Molecules, Connect This Biotech Basket

Pull the thread through all four, and the link is information. Guardant Health reads it from blood, Illumina sequences it, Eli Lilly turns it into medicines at a global scale, and Moderna rewrites it into personalized vaccines. Each gets sharper as data piles up, separating this group from old binary bets on a single trial.

The upside is a decade of compounding across testing, tools and therapy. The risks are elevated valuations after big runs, Moderna’s losses and the volatility that has always shadowed biotech. None of it pays off without adoption by insurers, regulators and labs.

Stay focused on adoption and data volume, because that’s what moves biointelligence stocks from science headlines into earnings.